16 completed, 5 unknown, 3 not yet recruiting, 2 recruiting. 30 Phase 2, 5 Phase 3, 2 Phase 1.
Follow Amantadine: new trials by email Literature Review of Amantadine trials Research Report on Amantadine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Amantadine (oral) - Breast Cancer, Peripheral Neuropathy Due to Chemotherapy | Phase 2 | Not yet recruiting | Al-Azhar University | 80 | 2026-12-01 | 2026-10-22 |
| Use of Gocovri to Improve Disability Due to Radiation Encephalopathy Gocovri (extended-release amantidine) - Encephalopathy, Radiation Effect | Phase 2 | Not yet recruiting | Weill Medical College of Cornell University | 24 | 2026-09-01 | 2026-08-03 |
| A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling - Long COVID, Post-Acute COVID-19 Syndrome | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2025-06-01 | 2025-08-26 | |
| The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial Amantadine (100mg) as add on therapy., Placebo - Parkinson Disease (PD) | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 132 | 2025-05-01 | 2025-02-10 |
| Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI). Amantadine Hydrochloride, Placebo - Traumatic Brain Injury | Phase 2 | Active not recruiting | SHINKEI Therapeutics, Inc | 45 | 2024-06-01 | 2025-07-15 |
| Amantadine Therapy for Cognitive Impairment in Long COVID Amantadine - Long COVID, Post-COVID19 Condition | Phase 2 | Completed | Ohio State University | 64 | 2023-12-07 | 2026-01-27 |
| Amantadine for Neuroenhancement in Acute Patients Study Amantadine - Disorder of Consciousness | Phase 2 | Unknown | University Hospital Tuebingen | 50 | 2023-03-01 | 2024-02-01 |
| The Effect of Amantadine on Post-COVD-19 Fatigue Amantadine - Post-COVID-19 Syndrome | Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 83 | 2022-12-26 | 2022-12-28 |
| Promoting Recovery After STroke With Amantadine Amantadine, Placebo - Stroke, Ischemic, Stroke Hemorrhagic | Phase 2 | Recruiting | University of Pennsylvania | 60 | 2022-02-01 | 2026-03-30 |
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial Memantine Hydrochloride Oral Solution, Trazodone Hydrochloride oral solution, Placebo oral solution - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Recruiting | University of Edinburgh | 1150 | 2020-02-27 | 2026-03-04 |
| Effect of Intravenous Amantadine Sulphate on Disorders of Consciousness Amantadine Sulfate - Amantadine, Consciousness Disorders | Phase 2 | Completed | Azienda Sanitaria dell'Alto Adige | 18 | 2018-09-15 | 2026-11-02 |
| Oral Amantadine, IV Amantadine and Hemodynamic Response to Laryngoscopy oral Amantadine sulfate, i.v Amantadine Sulfate, placebo tablet - Intubation, Intratracheal | Phase 2 | Unknown | Assiut University | 60 | 2018-08-15 | 2021-11-16 |
| Oral Amantadine Versus Gabapentin to Attenuate the Response to Laryngoscopy and Tracheal Intubation oral amantadine sulfate, oral gabapentin, Placebo Oral Tablet - Effect of Laryngoscopy and Tracheal Intubation | Phase 2 / Phase 3 | Completed | Ghada Mohammed AboelFadl | 90 | 2017-06-15 | 2018-09-25 |
| Amantadine to Speed Awakening After Cardiac Arrest Amantadine, Placebo - Coma, Heart Arrest | Phase 2 | Completed | Jon Rittenberger, MD | 14 | 2015-09-01 | 2019-12-04 |
| Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Topiramate, Placebo, Amantadine - Idiopathic Parkinson's Disease, Drug Induced Dyskinesia | Phase 2 | Terminated | Rush University Medical Center | 42 | 2013-03-01 | 2019-04-16 |
| Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease Amantadine, placebo - Parkinson Disease | Phase 2 | Completed | University Hospital, Toulouse | 210 | 2012-03-04 | 2026-04-06 |
| Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects Dextromethorphan hydrobromide, Amantadine, Pacebo 1 (placebo for Amantadine) - Type 2 Diabetes Mellitus | Phase 2 | Completed | Profil Institut für Stoffwechselforschung GmbH | 20 | 2011-09-01 | 2012-07-12 |
| Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications Amantadine, Ribavirin, Oseltamivir, Oseltamivir - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 881 | 2010-09-01 | 2019-02-04 |
| Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) Amantadine, ritalin - Attention Deficit Hyperactivity Disorder | Phase 2 | Unknown | Tehran University of Medical Sciences | 40 | 2010-04-01 | 2010-11-18 |
| Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects Oseltamivir Phosphate, ADS-8902 - Influenza | Phase 2 | Completed | Adamas Pharmaceuticals, Inc. | 2 | 2009-09-01 | 2014-04-14 |
Showing 20 of 30. Sign in to see all of them.
Parkinson Disease (4) · Cocaine-Related Disorders (3) · Consciousness Disorders (3) · Influenza, Human (3) · Post-Acute COVID-19 Syndrome (3) · Brain Injuries, Traumatic (2) · Dyskinesias (2) · Amyotrophic Lateral Sclerosis (1) · Attention Deficit Disorder with Hyperactivity (1) · Brain Diseases (1) · Breast Neoplasms (1) · Cerebral Infarction (1) · Chorea (1) · Coma (1) · Diabetes Mellitus, Type 2 (1)
University Hospital, Toulouse (2) · University of Pennsylvania (2) · Adamas Pharmaceuticals, Inc. (1) · Aga Khan University (1) · Al-Azhar University (1) · Assiut University (1) · Azienda Sanitaria dell'Alto Adige (1) · Centre Hospitalier Universitaire de Nice (1) · Fred Hutchinson Cancer Center (1) · Ghada Mohammed AboelFadl (1) · JFK Medical Center (1) · Jon Rittenberger, MD (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Ohio State University (1)
United States (15) · France (3) · Germany (3) · Australia (2) · Canada (2) · Egypt (2) · Iran (2) · Argentina (1) · Denmark (1) · Israel (1) · Italy (1) · Mexico (1) · Netherlands (1) · Pakistan (1) · Singapore (1)
Abualauon Elpiplaoy, MD (1) · Aeyal Raz, MD,PhD (1) · Alin O Stirban, MD (1) · Amy Mathews, M.D. (1) · Andrew I Schamess, MD (1) · Annerose Mengel, attending physician (1) · Christopher G Goetz, MD (1) · Ghada Abu El Fadl, MD (1) · Helen M. Pettinati, Ph.D. (1) · John Beigel, MD (1) · John Treanor, MD (1) · John Whyte, MD, Ph.D. (1)
PMID 16697124, PMID 22375973, PMID 22755276, PMID 23264438, PMID 24045608, PMID 28958678, PMID 35798516, PMID 36647114, PMID 36725099, PMID 37608315, PMID 39307154, PMID 41316871
2023 (1), P50DA009250 (1), P50DA009260 (1), P50DA012756 (1)